News
October 5th, 2022
TD2 Announces Dr. Alan Miller as New Chief Medical Officer
The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth. SCOTTSDALE, ARIZONA, UNITED STATES, October 5, 2022 /EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the addition of Dr. Alan Miller as their new Chief Medical Officer. Prior to joining TD2, Dr. Miller was Chief […]
August 25th, 2022
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, […]
August 9th, 2022
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid […]
May 12th, 2022
Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial
HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in patients with metastatic breast cancer. “This is a significant and exciting achievement for our company,” […]
April 5th, 2022
TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting
SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA., to be held April 8-13, 2022. Two posters […]
Events
December 7, 2022
Outsourcing in Clinical Trials
Houston, TX | Schedule a time to meet with us
December 10, 2022
American Society of Hematology
New Orleans, LA | Schedule time to meet with us